Tocilizumab is recommended, within its marketing authorisation, as an option for treating COVID-19 in adults who: 

  • are having systemic corticosteroids and 
  • need supplemental oxygen or mechanical ventilation.

 

This recommendation is from NICE’s technology appraisal guidance on casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab.

The summary of product characteristics for tocilizumab specifies that it should only be offered when there is no evidence of a bacterial or viral infection (other than SARS-CoV-2) that might be worsened by tocilizumab. It also states that the efficacy of tocilizumab has not been established in the treatment of COVID-19 in people who do not have elevated C-reactive protein levels.

 

Adapted from NICE COVID-19 rapid guideline: Managing COVID-19 - Therapeutics for COVID-19